QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

(₹ in Crores, except earning per share)

	Quarter ended Half year ended						Year ended
Sr. No	Particulars	September 30, 2023	June 30, 2023	September 30, 2022	September 30, 2023 September 30, 2022 March 31, 2		
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income					(0	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	Revenue from operations	78.36	51_44	100.94	129.80	162,02	278.0
	Other income	5.69	4.73	5.40	10.42	8.60	22.13
	Total income	84.05	56,17	106.34	140.22		300.2
				7000	710.22	110102	500,22
2	Expenses						
	Cost of raw materials consumed		0.41	0.42	0.41	0.65	1.1
	Purchase of software products	0.85	2.06	4.06	2,91	4.73	7, 8.
	Change in inventory of security software products	1,22	(1,46)	(0.68)	(0.24)		0,3
	Employee benefits expenses	41.70	39,33	39.45	81.03	76,57	154.9
	Depreciation and amortisation expense	3.25	2.93	4.14	6.18		15.9
	Other expenses	23.62	26.18	29.31	49.80	50.62	111.9
	Total expenses	70.64	69.45	76.70	140.09		292.20
	·						
3	Profit / (loss) before tax (1-2)	13.41	(13.28)	29.64	0.13	29.94	8.0
	Tront (1005) before tax (1-w)	15.41	(15.26)	27.04	0.13	29.94	0.0
4	Tax expense						
	Current tax						
	Pertaining to profit for the current year	0.31	1100	7,28	0.31	7.40	1.28
	Adjustment in respect of current tax and deferred tax of previous years (Net)	(*)	1961		100		(0.14
	Deferred tax	0,20	(0.52)	0.20	(0, 32)	0.20	0.48
	Total tax expense	0.51	(0.52)	7.48	(0.01)	7.60	1.62
.5	Profit / (loss) for the period (3-4)	12.90	(12.76)	22.16	0.14	22.34	6.4
6	Other comprehensive income / (loss) (net of tax)						
. 0	Items that will not be reclassified subsequently to profit or loss:						
	De accompany of the first base	0.74					
	Re-measurement of defined benefit plans	0.26	0.13	0.33	0.39		0.1
	Net (loss) or gain on FVTOCl assets	(12 55)	1 61	(0,61)	(12,55)	(0.61)	(5.9
	Items that will be reclassified subsequently to profit or loss:						
	Exchange differences on translation of foreign operations	0.02	(0.08)	(0.03)	(0.06)	(0.21)	(0.1
	Total other comprehensive income / (loss)	(12.27)	0.05	(0.31)	(12.22)	(1.12)	(5.9
7	Total comprehensive income / (loss) (after tax) (5+6)	0.63	(12.71)	21.85	(12.08)	21.22	0.4
8	Paid-up equity share capital (face value of ₹10 each)	53, 08	53.07	58 07	53.08	58.07	53.0
9	Other equity	3,00	53,07	3407	55.06	38.07	366.6
			-	-		-	300 0
10	Earnings per share of ₹10 each: (not annualised for the quarter)						*
	a) Basic	2 43	(2.40)	2.02	0.03	2.00	ν.
			(2 40)	3 82	0 03		1.1
	b) Diluted	2.42	(2.40)	3 81	0.03	3 84	





OUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

Notes to financial results:

- 1 The above financial results for the quarter and half year ended September 30, 2023 have been subjected to limited review by the statutory auditors of the Holding Company and reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on October 26, 2023.
- 2 The Board of Directors of the Holding Company at its meeting held on July 21, 2022 and the shareholders by way of postal ballot on August 26, 2022, approved the buy back of the Holding Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Holding Company including promoters of the Holding Company as on the record date, on a proportionate basis through the "tender offer" route at a price of \$\forall 300 per share for an aggregate amount not exceeding ₹ 150. The Holding Company completed the Buy Back Process on October 28, 2022 and has complied with all the requisite formalities with SEBI and ROC.

During the year ended March 31, 2023, as per the requirement of the Companies Act, 2013, an amount of ₹ 3.31 and ₹ 176.63 (Including tax on buy back of ₹ 34.94) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of \$ 5.00 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹ 5.00. Further, transaction cost of buy back of shares of ₹ 1.85 has been reduced from retained earnings.

- The following changes have taken place in Key Managerial Personnel of the Holding Company
 - Mr. Srinivasa Rao Anasingaraju resigned as Company Secretary w.e.f. July 17, 2023
 - Mr. Sarang Hari Deshpande appointed as Company Secretary w.e.f. October 26, 2023
- Considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment has recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly. entries carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at September 30, 2023.
- The Group is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

For and on behalf of the Board of Directors

chnolo,

Kailash Katkar Managing Director DIN No: 00397191

Place: Pune Date: October 26, 2023

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

STATEMENT OF UNAUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2023

		₹ in Crore
	As at September 30, 2023 (Unaudited)	As at March 31, 2023 (Audited)
Assets		(**************************************
Non-current assets		
(a) Property, plant and equipment	92.68	97.56
(b) Intangible assets	1.92	2.77
(c) Intangible assets under development	0.15	0.15
(d) Investment Property	27.62	24.12
(e) Financial assets	· 1	
(i) Investments	8.35	21.49
(ii) Other financial assets	0.82	0.76
(f) Income tax assets (net)	29.04	22.33
(g) Other non-current assets	0.70	0.65
	161.28	169.83
Current assets		
(a) Inventories	4.33	4.50
(b) Financial assets		
(i) Investments	163_58	176.20
(ii) Trade receivables	107.50	122.65
(iii) Cash and cash equivalents	12.79	11.58
(iv) Bank balances other than (iii) above	0.28	0.27
(v) Other financial assets	1.91	1.49
(c) Other current assets	9.91	6.78
	300.30	323,47
Total assets	461.58	493,30
Equity and liabilities		
Equity		
(a) Equity share capital	53.08	53,07
(b) Share application money pending allotment	0.11	
(c) Other equity	342.86	366.64
Total equity	396.05	419.71
Liabilities		
Non-current liabilities		
(a) Net employee defined benefit liabilities	2	0.60
(b) Other non-current liabilities	1.03	0.52
(c) Deferred tax liabilities (net)	0.35	0.53
Current liabilities	1.38	1.65
(a) Financial liabilities	Tild Control	
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	2.51	1.94
(b) Total outstanding dues creditors other than micro enterprises and enterprises	38.04	46.67
(ii) Other financial liabilities	8,44	12.73
(b) Other current liabilities	14.20	10.03
(c) Net employee defined benefit liabilities	0.96	0.57
(d) Income tax liabilities (net)	-	
Livrino 65 USA	64.15	71,94
Total liabilities	65,53	73.59
Fotal equity and liabilities	461.58	493,30





Quick Heal Technologies Limited

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

CONSOLIDATED STATEMENT OF UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2023

Adjustments for recensive profit before tax to not eight flows: Not (gint) Vious foreign exchange efficiences (0.14) Not (gint) Vious foreign exchange efficiences (1.42) Deprocision and maniferation expanse (1.43) Provision for doubtili debts and sof-neces (1.44) Provision for doubtili debts and sof-neces (1.45) Provision for doubtili debts and sof-neces (1.46) Provision for doubtili debts and sof-neces (1.47) Provision for doubtili debts and sof-neces (1.48) (1.49) Provision for doubtili debts and sof-neces (1.41) (1.40) Provision for doubtili debts and sof-neces (1.41) (1.40) Provision for doubtili debts and sof-neces (1.41) (1.40) Provision for doubtili debts and sof-neces (1.41) (1.41		D	₹ in Cror
A. Carb flow from operating activities Profit before tax Adjustment to receive profit before tax to not each flower. Librilly with bank Not (quite) Assa foreign exchange diffusivenee 1.42 Despressions and amorbisting acquired sepanee (a.18) Despressions and amorbisting acquired sepanee (b.18) Conversal foreign exchange diffusivenee (b.18) Conversal foreign exchange diffusivenee (c.18) Conversal foreign exchange diffusivenee (c.29) Conversal foreign exchange			
Process Proc		Chaudited	Addited
Process Proc	4.6.16.4		
Adjustments on recording pools before tax to not could flower. Carbolley write book Carbolley with the c			
Labibity wine back		0.13	8.0
Not Engine) / Joes foreign exchange differences 1.4.2 1.4.2 1.4.4 1.			
Employee share based gayomets expense 1.62 Depreciation and amonth/action expense 1.63 Depreciation and amonth/action expense 1.64 Depreciation and amonth/action expense 1.65 Description of amonth/action of provide progress with the provide provide of the control debts and advances Property, plant and equipment written off Control / Loss on alloe of property, plant and equipment Cold Description of the provide provide provide provide Description of the provide pro		*	(1.8
Deposition and manifestion appears 1.15		(0.14)	0.8
Interest secures		1,42	2.8
Provision for doubtful debts and advances 9.54 6.65 1.65	·	6.18	15.9
Property plant and equipment written off 0.00		0,04	(1.7)
Cready C		4.64	5.1
Exchange difference on translation of foreign currency cash and eash equivalents		0.03	2
	(Profit) / Loss on sale of property, plant and equipment	(0.28)	(3,9:
Net gain on self-pic. current investment	Exchange difference on translation of foreign currency cash and cash equivalents	(0.01)	
Met gain on able of investment (5,71)		(1.87)	(3.5)
Met jam on FVTPL current investment (section) 1.15 1	Net gain on sale of investment	(0,78)	(3.20
Increase Autority		(5.21)	(6.88
docements in working capital			11.59
(Increase)/decrease in inventionnes (Increase)/decrease in other financial assets (Increase)/decrease in other financial assets (Increase)/decrease in other assets (Increase)/decrease in other assets (Increase)/decrease in index patients (Increase)/decrease in index patients (Increase)/decrease in index patients (Increase)/decrease in interdepatients (Increase)/decrease) in trade papables (Increase)/decrease) in trade papables (Increase)/decrease) in other current and non current liabilities (Increase)/decrease paid (Increase)/decrease paid (Increase)/decrease paid (Increase)/decrease paid (Increase)/decrease in property, plant and equipment (Increase)/decrease in branch balances of investments (Increase)/decrease in branch balances other than cash and cash equivalents (Increase)/decrease in branch balances other than cash and cash equivalents (Increase)/decrease in branch balances other than cash and cash equivalents (Increase)/decrease in branch balances other than cash and cash equivalents (Increase)/decrease in branch balances other than cash and cash equivalents (Increase)/decrease in branch balances other than cash and cash equivalents (Increase)/decrease in branch balances (Including securities premium) on exercise of ESOP by (Increase)/decrease in branch balances (Including securities premium) on exercise of ESOP by (Increase)/decrease in cash and cash equivalents (Increase)/decrease in cash and cash equivalents (Increas			
(thereasy/decrease in inventionies (thereasy/decrease in other financial sasets (thereasy/decrease in other financial sasets (thereasy/decrease) in set employee defined benefit liabilities (a, 6, 6) (thereasy/decrease) in set employee defined benefit liabilities (a, 6, 6) (thereasy/decrease) in set employee defined benefit liabilities (a, 6, 6) (thereasy/decrease) in set employee defined benefit liabilities (a, 6, 6) (thereasy/decrease) in set employee defined benefit liabilities (a, 6, 6) (thereasy/decrease) in set employee defined benefit liabilities (a, 6, 6) (thereasy/decrease) in other dinancial liabilities (a, 6, 6) (a) (a) (a) (a) (a) (a) (a) (a) (a) (a	(Increase)/decrease in trade receivables	10.59	44.31
(Increase)/decrease in other financial assets (Increase)/decrease in other assets (Increase)/decrease in other assets (Increase)/decrease in other assets (Increase)/decrease) in ret employee defined benefit liabilities (Increase)/decrease) in other famacials liabilities (Increase)/decrease) in other current and non current liabilities (Increase)/decrease paid (net of refunds) (Increase)/decrease paid (net of refunds) (Increase)/decrease in decrease (Increase) (Increase)/decrease in decrease (Increase) (Increase)/decrease in decrease (Increase) (Increase)/decrease in decrease (Increase) (Increase)/decrease in decrease (Increase)/decrease (Increase)/de	(Increase)/decrease in inventories		0.29
(Increasy/decrease in other assets (Including capital work-in-progress and private taxes paid (act of treatment) (act of treatm			(0.88
Increase/(decrease) in net employee defined benefit liabilities 0.31 0.05			(3.38
Increase/(decrease) in trade payables (8.00) (3.00) (2.00)	Increase/(decrease) in net employee defined benefit liabilities	1	0.07
Increase/(decrease) in other financials liabilities			(1.08
Increase/decrease) in other current and non current liabilities 4.68 7.00	Increase/(decrease) in other financials liabilities		(2.83
Seath generated from operations S.67 3.88 (7.02) (8.00) (8.00) (7.02) (8.00) (8.00) (8.00) (8.00) (8.00) (8.00) (8.00) (8.00) (8.00) (8.00) (9.00)	Increase/(decrease) in other current and non current liabilities	11,000,000	(9.28
A	Cash generated from operations		38,81
Cash flow from investing activities (A) (1.35) 300	Direct taxes paid (net of refunds)		(8,00
Cash flow from investing activities	Net cash flow from operating activities (A)		30,81
Purchase of investments (146.84) (400 Sale of investments 166.04 524 Income from Investment Property 1.87 3 (Increase)/decrease in bank balances other than cash and cash equivalents (0.01) 54 Interest received (0.59) 1.1 et cash (used in) investing activities (B) 1.5.54 185 Cash flow from financing activities Dividen paid on equity shares (13.26) 2.66 Tax on Buyback 7 Proceeds from issuance of equity shares (13.26) 2.7 0. Et cash flow (used in) investing activities Premium) on exercise of ESOP by employees 1.27 0. Et cash flow (used in) financing activities (C) (12.99) (212. Et (decrease) in cash and cash equivalents (A+B+C) 1.20 3. Sh and cash equivalents at the beginning of the year 11.58 7. Get of exchange differences on cash and cash equivalents held in foreign currency 0.01 (0.00) Et cash flow (used in) financing activities (C) (12.99) 1.27 Exponent of cash and cash equivalents at the end of the year 12.79 11.20 Exponent of cash and cash equivalents (A+B+C) 1.20 2.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash and cash equivalents (A+B+C) 1.20 3.00 Exponent of cash exponent of cash equivalents (A+B+C) 1.20 3.00 Exponent of cash exp	B. Cash flow from investing activities Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(5,71)	(4.08
Sale of investments		0.78	5,20
Income from Investment Property Income from Investment Income (0.01) Interest received Income from Investing activities (B) Income Income from Investing activities (B) Income f		(146.84)	(400 60
(Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in bank balances other than cash and cash equivalents (Increase)/decrease in cash and cash equivalents (Increase)/decrease in cash and cash equivalents held in foreign currency (Increase)/decrease in cash and cash equivalents held in foreign currency (Increase)/decrease in cash and cash equivalents held in foreign currency (Increase)/decrease in cash and cash equivalents held in foreign currency (Increase)/decrease in cash and cash equivalents (Increase)/decrease in cash and cash equivalents held in foreign currency (Increase)/decrease in cash and cash equivalents (Increase)/decrease in cash and cash equivalents held in foreign currency (Increase)/decrease in cash and cash equivalents (Increase)/decrease in cash and cash equivalents (Increase)/decrease in cash and cash equivalents held in foreign currency (Increase)/decrease in cash and cash equivalents (Increase)/decrease in cash equivalents (166,04	524.53
(Increase)/decrease in bank balances other than eash and cash equivalents (0.01) Interest received (0.59) Interest received (0.59) It et cash (used in) investing activities (B) Cash flow from financing activities Dividend paid on equity shares (13.26) Cash Blow from financing activities Dividend paid on equity shares (13.26) Cash flow from financing activities Proceeds from issuance of equity shares (including securities premium) on exercise of ESOP by employees Buyback Expenses Payout on Buyback of equity shares (1.50) It cash flow (used in) financing activities (C) (12.99) Catl Cecrease) in cash and cash equivalents (A+B+C) Sh and cash equivalents at the beginning of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the end of the year feet of exchange differences on cash and cash equivalents held in foreign currency (1.50) Sh and cash equivalents at the e		1.87	3,58
Interest received (0.59) (1.54 185	(Increase)/decrease in bank balances other than cash and cash equivalents	(0.01)	54.74
et cash (used in) investing activities (B) Cash flow from financing activities Dividend paid on equity shares Tax on Buyback Proceeds from issuance of equity shares (including securities premium) on exercise of ESOP by employees Buyback Expenses Payout on Buyback of equity shares (Isober cash flow (used in) financing activities (C) (It (decrease) in cash and cash equivalents (A+B+C) (It (decrease) in cash and cash equivalents at the beginning of the year (It (shared of exchange differences on cash and cash equivalents held in foreign currency (Isober of exchange differences on cash and cash equivalents held in foreign currency (Isober of exchange differences on cash and cash equivalents held in foreign currency (Isober of exchange differences on cash and cash equivalents held in foreign currency (Isober of exchange differences on cash and cash equivalents held in foreign currency (Isober of exchange differences on cash and cash equivalents held in foreign currency (Isober of exchange differences on cash and cash equivalents held in foreign currency (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on cash and cash equivalents (Isober of exchange differences on	Interest received		1.86
Dividend paid on equity shares Tax on Buyback Proceeds from issuance of equity shares (including securities premium)on exercise of ESOP by employees Buyback Expenses Payout on Buyback of equity shares (150. et cash flow (used in) financing activities (C) (12.99) (212. et (decrease) in cash and cash equivalents (A+B+C) (150. sh and cash equivalents at the beginning of the year (151.58) (152. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (152. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (160. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (160. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (160. et of exchange differences on cash and cash equivalents held in foreign currency (160. et of exchange differences on cash and cash equivalents held in foreign currency (160. et of exchange differences on cash and cash equivalents held in foreign currency (160. et of exchange differences on cash and cash equivalents held in foreign currency (17.79) (17.79) (17.70) (1	Net cash (used in) investing activities (B)		185,23
Dividend paid on equity shares Tax on Buyback Proceeds from issuance of equity shares (including securities premium)on exercise of ESOP by employees Buyback Expenses Payout on Buyback of equity shares (150. et cash flow (used in) financing activities (C) (12.99) (212. et (decrease) in cash and cash equivalents (A+B+C) (150. sh and cash equivalents at the beginning of the year (151.58) (152. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (152. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (160. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (160. et of exchange differences on cash and cash equivalents held in foreign currency (151.58) (160. et of exchange differences on cash and cash equivalents held in foreign currency (160. et of exchange differences on cash and cash equivalents held in foreign currency (160. et of exchange differences on cash and cash equivalents held in foreign currency (160. et of exchange differences on cash and cash equivalents held in foreign currency (17.79) (17.79) (17.70) (1	Cook flow from Francisco (CV)		
Tax on Buyback Proceeds from issuance of equity shares (including securities premium) on exercise of ESOP by employees Buyback Expenses Payout on Buyback of equity shares et cash flow (used in) financing activities (C) (12,99) (212, et (decrease) in cash and cash equivalents (A+B+C) 1,20 3, sish and cash equivalents at the beginning of the year (etct of exchange differences on cash and cash equivalents held in foreign currency (a) sish and cash equivalents at the end of the year (b) sish and cash equivalents at the end of the year (c) sish and cash equivalents at the end of the year (d) sish and cash equival		0.5~	
Proceeds from issuance of equity shares (including securities premium) on exercise of ESOP by employees Buyback Expenses Payout on Buyback of equity shares (150. et cash flow (used in) financing activities (C) (12.99) (212. et (decrease) in cash and cash equivalents (A+B+C) 3. sh and cash equivalents at the beginning of the year feet of exchange differences on cash and cash equivalents held in foreign currency (ash and cash equivalents at the end of the year (but of exchange differences on cash and cash equivalents held in foreign currency (c) (c) (c) (c) (d) (d) (d) (d)		(13.26)	(26.09)
employees Buyback Expenses Payout on Buyback of equity shares (1.50) et cash flow (used in) financing activities (C) (12.99) (212. et (decrease) in cash and cash equivalents (A+B+C) 1.20 3. sh and cash equivalents at the beginning of the year (11.58 7. feet of exchange differences on cash and cash equivalents held in foreign currency 0.01 (0.98) and cash equivalents at the end of the year 11.79 11. emponents of cash and cash equivalents sh on hand lances with banks On current account 11.07 9.00 EEFC account	· · · · · · · · · · · · · · · · · · ·	10 8 3	(34.94)
Buyback Expenses Payout on Buyback of equity shares Let cash flow (used in) financing activities (C) Let (decrease) in cash and cash equivalents (A+B+C) Let (decrease) in cash and cash equivalents at the beginning of the year Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign currency Let of exchange differences on cash and cash equivalents held in foreign	Proceeds from issuance of equity shares (including securities premium)on exercise of ESOP by	0.27	0.72
Payout on Buyback of equity shares ct cash flow (used in) financing activities (C) ct (decrease) in cash and cash equivalents (A+B+C) 1.20 3. sh and cash equivalents at the beginning of the year feet of exchange differences on cash and cash equivalents held in foreign currency 11.58 7. feet of exchange differences on cash and cash equivalents held in foreign currency 12.79 11. cmponents of cash and cash equivalents sh on hand lances with banks On current account On EEFC account 11.07 9.00 11.07 11.07 9.00 11.07 9.00 11.07 11.07 9.00 11.07 11.07 9.00 11.07	· ·	G.E.	0.72
et cash flow (used in) financing activities (C) (12.99) (212. et (decrease) in cash and cash equivalents (A+B+C) 1.20 3. sish and cash equivalents at the beginning of the year feet of exchange differences on cash and cash equivalents held in foreign currency 11.58 7. 12.79 11. components of cash and cash equivalents sh on hand lances with banks On current account On EEFC account 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4 11.07 9.4		●	(1.85)
tet (decrease) in cash and cash equivalents (A+B+C) 1.20 3. sh and cash equivalents at the beginning of the year feet of exchange differences on cash and cash equivalents held in foreign currency 11.58 7. (0.1) 12.79 11.07 12.79 11.07			(150.00)
ish and cash equivalents at the beginning of the year feet of exchange differences on cash and cash equivalents held in foreign currency ish and cash equivalents at the end of the year 11.58 7. 12.79 11.07	et cash now (used in) financing activities (C)	(12,99)	(212.16)
feet of exchange differences on cash and cash equivalents held in foreign currency ash and cash equivalents at the end of the year 12.79 11.00 Imponents of cash and cash equivalents sh on hand Indices with banks On current account On EEFC account 11.07 11.07 2.00 11.02 11.02 11.03	et (decrease) in cash and cash equivalents (A+B+C)	1.20	3.88
feet of exchange differences on cash and cash equivalents held in foreign currency sh and cash equivalents at the end of the year 12.79 11. Imponents of cash and cash equivalents sh on hand lances with banks On current account 11.07 9.00 EEFC account 11.07 2.00 Telesch and each equivalents	ash and cash equivalents at the beginning of the year	11.58	7.83
Ish and cash equivalents at the end of the year 12.79 11. Imponents of cash and cash equivalents sh on hand lances with banks On current account On EEFC account 11.07 11.07 2.0	ffect of exchange differences on cash and cash equivalents held in foreign currency		(0.13)
Imponents of cash and cash equivalents sh on hand lances with banks On current account On EEFC account It leash and each equivalents It leash and each equivalents	ash and cash equivalents at the end of the year		11.58
sh on hand - 0.0 lances with banks On current account 11.07 9.0 On EEFC account 1.72 2.0			-1100
Index Inde	omponents of cash and cash equivalents		
On current account 11.07 9.4 On EEFC account 1.72 2.0	nsh on hand	<u> </u>	0.02
On EEFC account 1.72 2.0	lances with banks		
On EEFC account 1.72 2.0	On current account	11.07	9.47
tal cach and and annihilation	On EEFC account		2.09
	etal cash and cash equivalents	12.79	11.58





OUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

(₹ in Crores, except earning per share) Half year ended Year ended Quarter ended March 31, 2023 Sr. No Particulars September 30, 2023 June 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 (Unaudited) (Audited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Income 78,37 51.43 100.93 129.80 162.02 278.11 Revenue from operations 8.57 22.38 5.68 4.73 5.38 10.41 Other income 84.05 56.16 106.31 140.21 170.59 300.49 Total income 2 Expenses 0.41 0.42 0.41 0.65 1.11 Cost of raw materials consumed 0.84 4.06 2,90 7.83 Purchase of security software products 2.06 4.73 1,22 (1.46)(0.68)(0.24)0.02 0.39 Change in inventory of security software products 39.33 76.56 154.89 Employee benefits expenses 41,70 39.45 81.03 3.25 2.93 4.14 6.18 8.09 15.99 Depreciation and amortisation expense 23.63 26 29 29 34 49.92 50.56 111.09 Other expenses 70.64 69.56 76.73 140.20 140.61 291.30 Total expenses 13.41 (13.40)29.58 0.01 29.98 9.19 Profit / (loss) before exceptional items and tax (1-2) (0.10)Exceptional items (refer note 2) 9.29 13.41 (13.40)0.01 29.98 5 Profit / (loss) before tax (3-4) 29.58 Tax expense Current tax Pertaining to profit for the current year 031 7.27 0.31 7.37 1.25 Adjustments of current tax and deferred tax relating to earlier periods (Net) (0.14)(0.32) Deferred tax 0.20 (0.52) 0.20 0.20 0.48 0.51 (0.52)7,47 (0.01)7.57 1.59 Total tax expense 0.02 Profit / (loss) for the period (5-6) 12.90 (12.88)22.11 22.41 7.70 Other comprehensive income / (loss) (net of tax) Items that will not be reclassified subsequently to profit or loss: Re-measurement of defined benefit plans 0.26 0.13 0.33 0.39 (0.30)0.13 (5.99)(12.55)(0.61)(12.55)(0.61)Net (loss) or gain on FVTOCI assets (12.29)0.13 (0.28)(12.16)(0.91)(5.86)Total other comprehensive income/ (loss) Total comprehensive income / (loss) (after tax) (7+8) 0.61 (12.75)21.83 (12.14)21.50 1.84 Paid-up equity share capital (face value of ₹ 10 each) 53 08 53 07 58 07 53 08 58.07 53.07 366 65 11 Other equity Earnings per share of ₹ 10 each: (not annualized except for the year ended March)

2 43

2 42

(243)

(2.43

a) Basic

b) Diluted



3 81

3 80



3.86

3.85

1.38

1.37

OUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

Notes to financial results:

The above financial results for the quarter and half year ended September 30, 2023 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on October 26, 2023.

Reversal of Impairment of investments

Included in exceptional items

(₹ in crores)

Particulars	Standalone					
	Quarter ended			Half year ended		Year ended
	September 30, 2023	June 30, 2023	September 30, 2022	September 30, 2023	September 30, 2022	March 31, 2023
Δ.	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Reversal of Impairment of investments in wholly owned subsidiaries				-		(0.10)

The Board of Directors of the Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Company including promoters of the Company as on the record date, on a proportionate basis through the "tender offer" route at a price of ₹ 300 per share for an aggregate amount not exceeding ₹ 150. The Company completed the Buy Back Process on October 28, 2022 and has complied with all the requisite formalities with SEBI and ROC.

During the year ended March 31, 2023, as per the requirement of the Companies Act, 2013, an amount of \$\frac{\tau}{2}\$, 31 and \$\frac{\tau}{2}\$ 176,63 (Including tax on buy back of \$\frac{\tau}{2}\$ 4.94) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of ₹ 5.00 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹ 5.00. Further, transaction cost of buy back of shares of ₹ 1.85 has been reduced from retained earnings

- 4 The following changes have taken place in Key Managerial Personnel of the Company
 - Mr. Srinivasa Rao Anasingaraju resigned as Company Secretary w.e.f. July 17, 2023
 - Mr. Sarang Hari Deshpande appointed as Company Secretary w.e.f. October 26, 2023
- Considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment has recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly, the entries carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at September 30, 2023.
- The Company is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz, cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

For and on behalf of the Board of Directors

Kailash Katkar Managing Director

DIN No: 00397191

Place: Pune

Date: October 26, 2023

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
CIN: L72200MH1995PLC091408

STATEMENT OF UNAUDITED STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2023

		₹ in crore:
	As at	As at
	September 30, 2023	March 31, 2023
Assets	(Unaudited)	(Audited)
Non-current assets		
(a) Property, plant and equipment	02.60	
(b) Intangible assets	92.69	97.57
(c) Intangible assets under development	1.92	2.77
(d) Investment property	0.15	0.15
(e) Investments in subsidiaries	27.62	24.12
(f) Financial assets	0.81	0.81
Carlot Control		
(i) Investments	8.35	21.49
(ii) Other financial assets	0.82	0.76
(g) Income tax assets (net)	29.04	22,33
(h) Other non-current assets	0.70	0.65
	162.10	170.65
Current assets		
(a) Inventories	4.33	4.50
(b) Financial assets		
(i) Investments	163.58	176.20
(ii) Trade receivables	107.95	122.77
(iii) Cash and eash equivalents	11.46	10.29
(iv) Bank balances other than (iii) above	0.28	0.27
(v) Other financial assets	1.90	1.48
(c) Other current assets	9.89	6.73
	299.39	322,24
Total assets	461.49	492.89
Equity and liabilities		
Equity		
(a) Equity share capital	53.08	52.07
(b) Share application money pending allotment	0.11	53.07
(c) Other equity		2///5
Total equity	342.81 396.00	366.65 419.72
Liabilities		
Non-current liabilities		
(a) Net employee defined benefit liabilities	:81	0.60
(b) Other non-current liabilities	1.03	0.52
(c) Deferred tax liabilities (net)	0.35	0.53
	1.38	1,65
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	2,51	1.94
(b) Total outstanding dues creditors other than micro enterprises and enterprises	38.16	46.74
(ii) Other financial liabilities	8.44	12.73
(b) Other current liabilities	14.04	9.54
(c) Net employee defined benefit liabilities	0.96	0.57
	64.11	71.52
otal liabilities	65.49	73.17
otal equity and liabilities	461.49	492.89





Quick Heal Technologies Limited

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

STANDALONE STATEMENT OF UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2023

₹ in crores

· · · · · · · · · · · · · · · · · · ·	a	₹ in crores
	September 30, 2023	March 31, 2023
A. Cash flow from operating activities	Unaudited	Audited
Profit before tax	0.01	9.29
Adjustment to reconcile profit before tax to net cash flows:	0.01	9.29
Exceptional items		(0.10)
Liability Written back	5	(1.88)
Net (gain) / loss foreign exchange differences	0.08	(0.15)
Employee share based payments expense	1.42	2.85
Depreciation and amortization expense	6.18	15.99
Interest income	0 04	(1.78)
Provision for doubtful debts and advances	4 64	5.14
Property, plant and equipment written off	0.03	5.17
(Profit) / loss on sale of property, plant and equipment	(0.28)	(3.95)
Income from Investment Property	(1.87)	(3.58)
Net gain on sale of investment	(0.78)	(3.20)
Net (gain) on FVTPL current investment	(5.21)	(6.88)
Operating profit before working capital changes	4.26	11.75
Movements in working capital:		46.19
(Increase)/decrease in trade receivables	10,10	45.17
(Increase)/decrease in inventories	0.17	0.29
(Increase)/decrease in other financial assets	0.07	(0.86)
(Increase)/decrease in other assets	(3.21)	(3.41)
Increase/(decrease) in net employee defined benefit liabilities	0,31	0.07
Increase/(decrease) in trade payables	(8.01)	(1,51)
Increase/(decrease) in other financials liabilities	(3.06)	(2.83)
Increase/(decrease) in other current and non-current liabilities	5.01	(9.75)
Cash generated from operations	5.64	38,92
Direct taxes paid (net of refunds)	(7.02)	(7.93)
Net cash flow from operating activities (A)	(1,38)	30.99
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-	(5.71)	(4.10)
progress and capital advances)		
Proceeds from sale of property, plant and equipment	0.78	5.20
Repatriation of funds / (Investments in subsidiaries)	16	2.27
Purchase of current investments	(146.84)	(400.60)
Sale of current investments	166.04	524.54
Income from Investment Property	1.87	3.58
(Increase)/decrease in bank deposits other than cash and cash equivalents	(0.01)	54.75
Interest received	(0.59)	1.86
Net cash (used in) investing activities (B)	15.54	187,50
C. Cash flow from financing activities Dividend paid on equity shares	(13.26)	(26,10)
Tax on Buyback	(13.20)	(34,94)
		(1.85)
Buyback Expenses Proceeds from issuance of equity shares (including securities premium) on exercise of ESOP	0.27	0.72
by employees	0,27	0.72
Payout for buyback of shares	_ []	(150.00)
Net cash flow (used in) financing activities (C)	(12.99)	(212.17)
	1.17	6,32
Net increase / (decrease) in cash and cash equivalents (A+B+C)		
Cash and cash equivalents at the beginning of the year	10.29	3.97
Cash and cash equivalents at the end of the period	11,46	10.29
Components of cash and cash equivalents		0.00
Cash on hand	(4)	0.02
Balances with banks	2 - 1	0.10
On current account	9,74	8 18
On EEFC account	1.72	2.09
Fotal cash and cash equivalents	11.46	10.29



